{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T16:10:00Z","timestamp":1771863000143,"version":"3.50.1"},"reference-count":179,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.addr.2022.114616","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T12:57:03Z","timestamp":1667825823000},"page":"114616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Gene editing strategies to treat lysosomal disorders: The example of mucopolysaccharidoses"],"prefix":"10.1016","volume":"191","author":[{"given":"Fl\u00e1via Nathiely Silveira","family":"Fachel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lariane","family":"Fr\u00e2ncio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9dina","family":"Poletto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roselena Silvestri","family":"Schuh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helder Ferreira","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Giugliani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme","family":"Baldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4977-6662","authenticated-orcid":false,"given":"Ursula","family":"Matte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2022.114616_b0005","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrm2745","article-title":"Lysosome biogenesis and lysosomal membrane proteins: Trafficking meets function","volume":"10","author":"Saftig","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.addr.2022.114616_b0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1590\/1678-4685-gmb-2018-0159","article-title":"Lysosomal diseases: Overview on current diagnosis and treatment","volume":"42","author":"Poswar","year":"2019","journal-title":"Genet. Mol. Biol."},{"key":"10.1016\/j.addr.2022.114616_b0015","first-page":"1","article-title":"Disruption of morphogenic and growth pathways in lysosomal storage diseases","volume":"13","author":"Corr\u00eaa","year":"2021","journal-title":"WIREs Mech. Dis."},{"key":"10.1016\/j.addr.2022.114616_b0020","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1083\/jcb.201208152","article-title":"Lysosomal storage disorders: The cellular impact of lysosomal dysfunction","volume":"199","author":"Platt","year":"2012","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.addr.2022.114616_b0025","unstructured":"V. Rajkumar, V. Dumpa, Lysosomal storage disease, 2022. \/\/www.ncbi.nlm.nih.gov\/books\/NBK563270\/."},{"key":"10.1016\/j.addr.2022.114616_b0030","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41436-018-0129-y","article-title":"The New York pilot newborn screening program for lysosomal storage diseases: Report of the First 65,000 Infants","volume":"21","author":"Wasserstein","year":"2019","journal-title":"Genet. Med."},{"key":"10.1016\/j.addr.2022.114616_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms18020441","article-title":"A review of gaucher disease pathophysiology, clinical presentation and treatments","volume":"18","author":"Stirnemann","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2022.114616_b0040","article-title":"Prevalence of lysosomal storage disorders in Australia from 2009 to 2020","volume":"19","author":"Chin","year":"2022","journal-title":"Lancet Reg. Health Wets. Pac."},{"key":"10.1016\/j.addr.2022.114616_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15252\/emmm.202012836","article-title":"The rapidly evolving view of lysosomal storage diseases","volume":"13","author":"Parenti","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.addr.2022.114616_b0050","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jamapediatrics.2015.0754","article-title":"Inborn errors of metabolism: Advances in diagnosis and therapy","volume":"169","author":"Vernon","year":"2015","journal-title":"JAMA Pediatr."},{"key":"10.1016\/j.addr.2022.114616_b0055","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ymgmr.2017.08.001","article-title":"The prevalence of diseases caused by lysosome-related genes in a cohort of undiagnosed patients","volume":"13","author":"Vairo","year":"2017","journal-title":"Mol. Genet. Metab. Reports."},{"key":"10.1016\/j.addr.2022.114616_b0060","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrd.2017.214","article-title":"Emptying the stores: Lysosomal diseases and therapeutic strategies","volume":"17","author":"Platt","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2022.114616_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17071065","article-title":"Less is more: Substrate reduction therapy for lysosomal storage disorders","volume":"17","author":"Coutinho","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2022.114616_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biom11121775","article-title":"Therapeutic approaches in lysosomal storage diseases","volume":"11","author":"Fern\u00e1ndez-Pereira","year":"2021","journal-title":"Biomolecules."},{"key":"10.1016\/j.addr.2022.114616_b0075","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2018.01.003","article-title":"Clinical presentation and diagnosis of mucopolysaccharidoses","volume":"125","author":"Stapleton","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2022.114616_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.spen.2021.100874","article-title":"Update in the Mucopolysaccharidoses","volume":"37","author":"McBride","year":"2021","journal-title":"Semin. Pediatr. Neurol."},{"key":"10.1016\/j.addr.2022.114616_b0085","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics10030172","article-title":"Diagnosis of mucopolysaccharidoses","volume":"10","author":"Kubaski","year":"2020","journal-title":"Diagnostics."},{"key":"10.1016\/j.addr.2022.114616_b0090","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.5582\/irdr.2020.01011","article-title":"A basic understanding of mucopolysaccharidosis: Incidence, clinical features, diagnosis, and management","volume":"9","author":"Zhou","year":"2020","journal-title":"Intractable Rare Dis. Res."},{"key":"10.1016\/j.addr.2022.114616_b0095","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1590\/S1415-47572012000600006","article-title":"Mucopolysacccharidoses: From understanding to treatment, a century of discoveries","volume":"35","author":"Giugliani","year":"2012","journal-title":"Genet. Mol. Biol."},{"key":"10.1016\/j.addr.2022.114616_b0100","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics11020273","article-title":"Epidemiology of mucopolysaccharidoses","volume":"11","author":"Celik","year":"2021","journal-title":"Diagnostics."},{"key":"10.1016\/j.addr.2022.114616_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-020-01608-0","article-title":"Estimated prevalence of mucopolysaccharidoses from population-based exomes and genomes","volume":"15","author":"Borges","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.addr.2022.114616_b0110","doi-asserted-by":"crossref","unstructured":"J. Sheth, M. Mistri, K. Shah, M. Chaudhary, K. Godbole, F. Sheth, Lysosomal Storage Disorders in Nonimmune Hydrops Fetalis (NIHF): An Indian Experience BT - JIMD Reports, Volume 35, in: E. Morava, M. Baumgartner, M. Patterson, S. Rahman, J. Zschocke, V. Peters (Eds.), Springer Berlin Heidelberg, Berlin, Heidelberg, 2017: pp. 47\u201352. 10.1007\/8904_2016_24.","DOI":"10.1007\/8904_2016_24"},{"key":"10.1016\/j.addr.2022.114616_b0115","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4331\/wjbc.v6.i3.110","article-title":"Biology of hyaluronan: Insights from genetic disorders of hyaluronan metabolism","volume":"6","author":"Triggs-Raine","year":"2015","journal-title":"World J. Biol. Chem."},{"key":"10.1016\/j.addr.2022.114616_b0120","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ymgme.2018.07.001","article-title":"Critical review of current MPS guidelines and management","volume":"126","author":"Stapleton","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2022.114616_b0125","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041204","article-title":"Underestimated aspect of mucopolysaccharidosis pathogenesis: Global changes in cellular processes revealed by transcriptomic studies","volume":"21","author":"Gaffke","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2022.114616_b0130","doi-asserted-by":"crossref","unstructured":"F. Kubaski, F. de Oliveira Poswar, K. Michelin-Tirelli, U. da Silveira Matte, D.D. Horovitz, A.L. Barth, G. Baldo, F. Vairo, R. Giugliani, Mucopolysaccharidosis type I, Diagnostics. (2020). 10.3390\/diagnostics10030161.","DOI":"10.3390\/diagnostics10030161"},{"key":"10.1016\/j.addr.2022.114616_b0135","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/cge.13224","article-title":"Worldwide distribution of common IDUA pathogenic variants","volume":"94","author":"Poletto","year":"2018","journal-title":"Clin. Genet."},{"key":"10.1016\/j.addr.2022.114616_b0140","doi-asserted-by":"crossref","unstructured":"F. D\u02b9Avanzo, L. Rigon, A. Zanetti, R. Tomanin, Mucopolysaccharidosis type II: One hundred years of research, diagnosis, and treatment, Int. J. Mol. Sci. 21 (2020). 10.3390\/ijms21041258.","DOI":"10.3390\/ijms21041258"},{"key":"10.1016\/j.addr.2022.114616_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.mrrev.2021.108392","article-title":"A molecular genetics view on Mucopolysaccharidosis Type II","volume":"788","author":"Verma","year":"2021","journal-title":"Mutat. Res. - Rev. Mutat. Res."},{"key":"10.1016\/j.addr.2022.114616_b0150","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s10545-008-0838-5","article-title":"Sanfilippo syndrome: A mini-review","volume":"31","author":"Valstar","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.addr.2022.114616_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21217819","article-title":"Sanfilippo syndrome: Molecular basis, disease models and therapeutic approaches","volume":"21","author":"Benet\u00f3","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2022.114616_b0160","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041517","article-title":"Mucopolysaccharidosis IVA: Diagnosis, treatment, and management","volume":"21","author":"Sawamoto","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2022.114616_b0165","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ymgme.2021.01.008","article-title":"Morquio B disease: From pathophysiology towards diagnosis","volume":"132","author":"Caciotti","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2022.114616_b0170","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/humu.23613","article-title":"Mucopolysaccharidosis type VI (MPS VI) and molecular analysis: Review and classification of published variants in the ARSB gene","volume":"39","author":"Tomanin","year":"2018","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.addr.2022.114616_b0175","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222413456","article-title":"Mucopolysaccharidosis type VI, an updated overview of the disease","volume":"22","author":"D\u2019Avanzo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2022.114616_b0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-021-01870-w","article-title":"Mucopolysaccharidosis VII in Brazil: natural history and clinical findings","volume":"16","author":"Giugliani","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.addr.2022.114616_b0185","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.gene.2015.09.062","article-title":"Large scale analysis of the mutational landscape in \u03b2-glucuronidase: A major player of mucopolysaccharidosis type VII","volume":"576","author":"Khan","year":"2016","journal-title":"Gene"},{"key":"10.1016\/j.addr.2022.114616_b0190","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nrg2842","article-title":"Genome editing with engineered zinc finger nucleases","volume":"11","author":"Urnov","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.addr.2022.114616_b0195","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrg3686","article-title":"A guide to genome engineering with programmable nucleases","volume":"15","author":"Kim","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.addr.2022.114616_b0200","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1126\/science.1138140","article-title":"CRISPR provides acquired resistance against viruses in prokaryotes","volume":"315","author":"Barrangou","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.addr.2022.114616_b0205","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s00239-004-0046-3","article-title":"Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements","volume":"60","author":"Mojica","year":"2005","journal-title":"J. Mol. Evol."},{"key":"10.1016\/j.addr.2022.114616_b0210","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.addr.2022.114616_b0215","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.1232033","article-title":"RNA-guided human genome engineering via Cas9","volume":"339","author":"Mali","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.addr.2022.114616_b0220","doi-asserted-by":"crossref","first-page":"e00471","DOI":"10.7554\/eLife.00471","article-title":"RNA-programmed genome editing in human cells","volume":"2","author":"Jinek","year":"2013","journal-title":"Elife."},{"key":"10.1016\/j.addr.2022.114616_b0225","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","article-title":"CRISPR-Cas9 Structures and Mechanisms","volume":"46","author":"Jiang","year":"2017","journal-title":"Annu. Rev. Biophys."},{"key":"10.1016\/j.addr.2022.114616_b0230","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.00024","article-title":"Studying DNA Double-Strand Break Repair: An Ever-Growing Toolbox","volume":"7","author":"V\u00edtor","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.addr.2022.114616_b0235","doi-asserted-by":"crossref","first-page":"e1004086","DOI":"10.1371\/journal.pgen.1004086","article-title":"Is Non-Homologous End-Joining Really an Inherently Error-Prone Process?","volume":"10","author":"B\u00e9termier","year":"2014","journal-title":"PLOS Genet."},{"key":"10.1016\/j.addr.2022.114616_b0240","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/bs.pmbts.2021.01.014","article-title":"Creating cell lines for mimicking diseases","volume":"181","author":"Poletto","year":"2021","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.addr.2022.114616_b0245","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1038\/mt.2013.111","article-title":"Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients","volume":"21","author":"Ousterout","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2022.114616_b0250","article-title":"Methods Favoring Homology-Directed Repair Choice in Response to CRISPR\/Cas9 Induced-Double Strand Breaks","volume":"21","author":"Yang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2022.114616_b0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21020500","article-title":"Genome editing for mucopolysaccharidoses","volume":"21","author":"Poletto","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2022.114616_b0260","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejpb.2017.10.017","article-title":"Gene editing of MPS I human fibroblasts by co-delivery of a CRISPR\/Cas9 plasmid and a donor oligonucleotide using nanoemulsions as nonviral carriers","volume":"122","author":"Schuh","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2022.114616_b0265","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.gene.2018.08.004","article-title":"CRISPR-Cas9-mediated gene editing in human MPS I fibroblasts","volume":"678","author":"de Carvalho","year":"2018","journal-title":"Gene"},{"key":"10.1016\/j.addr.2022.114616_b0270","doi-asserted-by":"crossref","unstructured":"K. Laoharawee, R.C. DeKelver, K.M. Podetz-Pedersen, M. Rohde, S. Sproul, H.-O. Nguyen, T. Nguyen, S.J. St Martin, L. Ou, S. Tom, R. Radeke, K.E. Meyer, M.C. Holmes, C.B. Whitley, T. Wechsler, R.S. McIvor, Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated InVivo Genome Editing., Mol. Ther. 26 (2018) 1127\u20131136. 10.1016\/j.ymthe.2018.03.002.","DOI":"10.1016\/j.ymthe.2018.03.002"},{"key":"10.1016\/j.addr.2022.114616_b0275","doi-asserted-by":"crossref","unstructured":"L. Ou, R.C. DeKelver, M. Rohde, S. Tom, R. Radeke, S.J. St Martin, Y. Santiago, S. Sproul, M.J. Przybilla, B.L. Koniar, K.M. Podetz-Pedersen, K. Laoharawee, R.D. Cooksley, K.E. Meyer, M.C. Holmes, R.S. McIvor, T. Wechsler, C.B. Whitley, ZFN-Mediated InVivo Genome Editing Corrects Murine Hurler Syndrome., Mol. Ther. 27 (2019) 178\u2013187. 10.1016\/j.ymthe.2018.10.018.","DOI":"10.1016\/j.ymthe.2018.10.018"},{"key":"10.1016\/j.addr.2022.114616_b0280","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1089\/hum.2018.169","article-title":"New Human Chromosomal Sites with \u201cSafe Harbor\u201d Potential for Targeted Transgene Insertion","volume":"30","author":"Pellenz","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.addr.2022.114616_b0285","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1038\/s41467-019-11962-8","article-title":"Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I","volume":"10","author":"Gomez-Ospina","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2022.114616_b0290","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.omtm.2022.04.009","article-title":"Improved engraftment and therapeutic efficacy by human genome edited hematopoietic stem cells with Busulfan-based myeloablation","volume":"25","author":"Poletto","year":"2022","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"10.1016\/j.addr.2022.114616_b0295","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jconrel.2018.08.031","article-title":"In vivo genome editing of mucopolysaccharidosis I mice using the CRISPR\/Cas9 system","volume":"288","author":"Schuh","year":"2018","journal-title":"J. Control. Release."},{"key":"10.1016\/j.addr.2022.114616_b0300","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1038\/s41467-020-17148-x","article-title":"Engineering monocyte\/macrophage-specific glucocerebrosidase expression in human hematopoietic stem cells using genome editing","volume":"11","author":"Scharenberg","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2022.114616_b0305","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41598-017-18911-9","article-title":"Development of versatile non-homologous end joining-based knock-in module for genome editing","volume":"8","author":"Sawatsubashi","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2022.114616_b0310","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nature20565","article-title":"In vivo genome editing via CRISPR\/Cas9 mediated homology-independent targeted integration","volume":"540","author":"Suzuki","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.addr.2022.114616_b0315","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s10038-017-0352-4","article-title":"In vivo genome editing via the HITI method as a tool for gene therapy","volume":"63","author":"Suzuki","year":"2018","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.addr.2022.114616_b0320","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.omtm.2021.01.001","article-title":"Non-viral ex vivo genome-editing in mouse bona fide hematopoietic stem cells with CRISPR\/Cas9","volume":"20","author":"Byambaa","year":"2021","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"10.1016\/j.addr.2022.114616_b0325","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.addr.2022.114616_b0330","doi-asserted-by":"crossref","unstructured":"S.K. Bose, B.M. White, M. V Kashyap, A. Dave, F.R. De Bie, H. Li, K. Singh, P. Menon, T. Wang, S. Teerdhala, V. Swaminathan, H.A. Hartman, S. Jayachandran, P. Chandrasekaran, K. Musunuru, R. Jain, D.B. Frank, P. Zoltick, W.H. Peranteau, In utero adenine base editing corrects multi-organ pathology in a lethal lysosomal storage disease., Nat. Commun. 12 (2021) 4291. 10.1038\/s41467-021-24443-8.","DOI":"10.1038\/s41467-021-24443-8"},{"key":"10.1016\/j.addr.2022.114616_b0335","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.addr.2022.114616_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107689","article-title":"Detection of Deleterious On-Target Effects after HDR-Mediated CRISPR Editing","volume":"31","author":"Weisheit","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.addr.2022.114616_b0345","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1038\/s41586-018-0380-z","article-title":"Large deletions induced by Cas9 cleavage","volume":"560","author":"Adikusuma","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.addr.2022.114616_b0350","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41588-020-0623-4","article-title":"Cas9 activates the p53 pathway and selects for p53-inactivating mutations","volume":"52","author":"Enache","year":"2020","journal-title":"Nat. Genet."},{"key":"10.1016\/j.addr.2022.114616_b0355","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-019-09006-2","article-title":"CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations","volume":"10","author":"Cullot","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2022.114616_b0360","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41588-021-00838-7","article-title":"Chromothripsis as an on-target consequence of CRISPR\u2013Cas9 genome editing","volume":"53","author":"Leibowitz","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.addr.2022.114616_b0365","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.cell.2020.10.025","article-title":"Allele-Specific Chromosome Removal after Cas9 Cleavage in Human Embryos","volume":"183","author":"Zuccaro","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.addr.2022.114616_b0370","doi-asserted-by":"crossref","DOI":"10.3390\/cells9071608","article-title":"Latest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing","volume":"9","author":"Naeem","year":"2020","journal-title":"Cells."},{"key":"10.1016\/j.addr.2022.114616_b0375","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41587-020-0565-5","article-title":"The delivery challenge: fulfilling the promise of therapeutic genome editing","volume":"38","author":"van Haasteren","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2022.114616_b0380","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s11427-017-9033-0","article-title":"Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field","volume":"60","author":"He","year":"2017","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.addr.2022.114616_b0385","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","article-title":"Delivering CRISPR: a review of the challenges and approaches","volume":"25","author":"Lino","year":"2018","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2022.114616_b0390","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/cbic.201800629","article-title":"Delivery of CRISPR\/Cas9 by Novel Strategies for Gene Therapy","volume":"20","author":"Wang","year":"2019","journal-title":"ChemBioChem"},{"key":"10.1016\/j.addr.2022.114616_b0395","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s40259-021-00500-y","article-title":"Targeting the Inside of Cells with Biologicals: Chemicals as a Delivery Strategy","volume":"35","author":"Marschall","year":"2021","journal-title":"BioDrugs."},{"key":"10.1016\/j.addr.2022.114616_b0400","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.biomaterials.2018.04.031","article-title":"Non-viral delivery systems for CRISPR\/Cas9-based genome editing: Challenges and opportunities","volume":"171","author":"Li","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2022.114616_b0405","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nbt.3471","article-title":"Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo","volume":"34","author":"Yin","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2022.114616_b0410","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jconrel.2016.11.014","article-title":"Delivery methods for site-specific nucleases: Achieving the full potential of therapeutic gene editing","volume":"244","author":"Liu","year":"2016","journal-title":"J. Control. Release."},{"key":"10.1016\/j.addr.2022.114616_b0415","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2022.01.013","article-title":"Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges","volume":"342","author":"Taha","year":"2022","journal-title":"J. Control. Release."},{"key":"10.1016\/j.addr.2022.114616_b0420","article-title":"CRISPR\/Cas9 Delivery System Engineering for Genome Editing in Therapeutic Applications","volume":"13","author":"Cheng","year":"2021","journal-title":"Pharm."},{"key":"10.1016\/j.addr.2022.114616_b0425","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/anie.201610209","article-title":"Non-Viral CRISPR\/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co-Delivery of Cas9 mRNA and sgRNA","volume":"56","author":"Miller","year":"2017","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.addr.2022.114616_b0430","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.cell.2014.01.027","article-title":"Generation of Gene-Modified Cynomolgus Monkey via Cas9\/RNA-Mediated Gene Targeting in One-Cell Embryos","volume":"156","author":"Niu","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.addr.2022.114616_b0435","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/jor.22745","article-title":"Targeting Cdk11 in osteosarcoma cells using the CRISPR-cas9 system","volume":"33","author":"Feng","year":"2015","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.addr.2022.114616_b0440","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2014.38","article-title":"The CRISPR\/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo","volume":"3","author":"Lin","year":"2014","journal-title":"Mol. Ther. - Nucleic Acids."},{"key":"10.1016\/j.addr.2022.114616_b0445","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nbt.2884","article-title":"Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype","volume":"32","author":"Yin","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2022.114616_b0450","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.addr.2020.07.004","article-title":"Progress and challenges towards CRISPR\/Cas clinical translation","volume":"154\u2013155","author":"Rosenblum","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114616_b0455","doi-asserted-by":"crossref","unstructured":"D. Kostyushev, A. Kostyusheva, S. Brezgin, V. Smirnov, E. Volchkova, A. Lukashev, V. Chulanov, Gene Editing by Extracellular Vesicles., Int. J. Mol. Sci. 21 (2020). 10.3390\/ijms21197362.","DOI":"10.3390\/ijms21197362"},{"key":"10.1016\/j.addr.2022.114616_b0460","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1002\/cbic.202100359","article-title":"Exosomes as Targeted Delivery Platform of CRISPR\/Cas9 for Therapeutic Genome Editing","volume":"22","author":"Duan","year":"2021","journal-title":"ChemBioChem"},{"key":"10.1016\/j.addr.2022.114616_b0465","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jconrel.2017.09.013","article-title":"Cancer-derived exosomes as a delivery platform of CRISPR\/Cas9 confer cancer cell tropism-dependent targeting","volume":"266","author":"Kim","year":"2017","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.addr.2022.114616_b0470","doi-asserted-by":"crossref","unstructured":"Y. Lin, J. Wu, W. Gu, Y. Huang, Z. Tong, L. Huang, J. Tan, Exosome-Liposome Hybrid Nanoparticles Deliver CRISPR\/Cas9 System in MSCs, Adv. Sci. (Weinheim, Baden-Wurttemberg, Ger. 5 (2018) 1700611. 10.1002\/advs.201700611.","DOI":"10.1002\/advs.201700611"},{"key":"10.1016\/j.addr.2022.114616_b0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113837","article-title":"Interest of extracellular vesicles in regards to lipid nanoparticle based systems for intracellular protein delivery","volume":"176","author":"Le Saux","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114616_b0480","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1161\/CIRCRESAHA.115.304351","article-title":"Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing","volume":"115","author":"Ding","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.addr.2022.114616_b0485","doi-asserted-by":"crossref","first-page":"e115987","DOI":"10.1371\/journal.pone.0115987","article-title":"CCR5 Gene Disruption via Lentiviral Vectors Expressing Cas9 and Single Guided RNA Renders Cells Resistant to HIV-1 Infection","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2022.114616_b0490","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cell.2020.03.023","article-title":"CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors","volume":"181","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.addr.2022.114616_b0495","doi-asserted-by":"crossref","DOI":"10.3390\/genes11101113","article-title":"Delivery Approaches for Therapeutic Genome Editing and Challenges","volume":"11","author":"Ates","year":"2020","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.addr.2022.114616_b0500","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.celrep.2016.09.002","article-title":"Super-Enhancers at the Nanog Locus Differentially Regulate Neighboring Pluripotency-Associated Genes","volume":"17","author":"Blinka","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.addr.2022.114616_b0505","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nchembio.1793","article-title":"Small molecule\u2013triggered Cas9 protein with improved genome-editing specificity","volume":"11","author":"Davis","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.addr.2022.114616_b0510","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nbt.3081","article-title":"Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo","volume":"33","author":"Zuris","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2022.114616_b0515","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jcis.2018.06.058","article-title":"Physicochemical properties of cationic nanoemulsions and liposomes obtained by microfluidization complexed with a single plasmid or along with an oligonucleotide: implications for CRISPR\/Cas technology","volume":"530","author":"Schuh","year":"2018","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.addr.2022.114616_b0520","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.2147\/IJN.S199104","article-title":"Cholesterol-rich lipid-mediated nanoparticles boost of transfection efficiency, utilized for gene editing by CRISPR-Cas9","volume":"14","author":"Hosseini","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.addr.2022.114616_b0525","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1021\/acs.bioconjchem.8b00856","article-title":"Synthesis and Evaluation of pH-Sensitive Multifunctional Lipids for Efficient Delivery of CRISPR\/Cas9 in Gene Editing","volume":"30","author":"Sun","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2022.114616_b0530","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2217\/nnm-2020-0412","article-title":"Special Focus Issue Part II: Recruitment of solid lipid nanoparticles for the delivery of CRISPR\/Cas9: primary evaluation of anticancer gene editing","volume":"16","author":"Akbaba","year":"2021","journal-title":"Nanomedicine (Lond)."},{"key":"10.1016\/j.addr.2022.114616_b0535","article-title":"Cationic nanoemulsions as potential carriers for intracellular delivery","author":"Khachane","year":"2014","journal-title":"Saudi Pharm. J."},{"key":"10.1016\/j.addr.2022.114616_b0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113834","article-title":"Nucleic acid delivery for therapeutic applications","volume":"178","author":"Gupta","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114616_b0545","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jconrel.2006.06.024","article-title":"Cationic lipids, lipoplexes and intracellular delivery of genes","volume":"116","author":"Wasungu","year":"2006","journal-title":"J. Control. Release."},{"key":"10.1016\/j.addr.2022.114616_b0550","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ijpharm.2017.10.030","article-title":"Cationic nanoemulsions as nucleic acids delivery systems","volume":"534","author":"Teixeira","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2022.114616_b0555","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.addr.2022.114616_b0560","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ijpharm.2017.10.030","article-title":"Cationic nanoemulsions for nucleic acids delivery","volume":"534","author":"Teixeira","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2022.114616_b0565","article-title":"Nasal Administration of Cationic Nanoemulsions as CD73-siRNA Delivery System for Glioblastoma Treatment: a New Therapeutical Approach","author":"Azambuja","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.addr.2022.114616_b0570","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ymthe.2019.01.014","article-title":"Genome Editing with mRNA Encoding ZFN, TALEN, and Cas9","volume":"27","author":"Zhang","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2022.114616_b0575","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1038\/s41467-020-17029-3","article-title":"Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing","volume":"11","author":"Wei","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2022.114616_b0580","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.tibtech.2017.11.006","article-title":"Engineering the Delivery System for CRISPR-Based Genome Editing","volume":"36","author":"Glass","year":"2018","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.addr.2022.114616_b0585","doi-asserted-by":"crossref","first-page":"7107","DOI":"10.1038\/srep07107","article-title":"The role of the helper lipid on the DNA transfection efficiency of lipopolyplex formulations","volume":"4","author":"Du","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2022.114616_b0590","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.tibtech.2018.08.010","article-title":"Non-Viral Delivery To Enable Genome Editing","volume":"37","author":"Rui","year":"2019","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.addr.2022.114616_b0595","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A Single Administration of CRISPR\/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.addr.2022.114616_b0600","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1089\/hum.2019.312","article-title":"Human Papillomavirus Oncogene Manipulation Using Clustered Regularly Interspersed Short Palindromic Repeats\/Cas9 Delivered by pH-Sensitive Cationic Liposomes","volume":"31","author":"Zhen","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.addr.2022.114616_b0605","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1021\/jacs.7b11754","article-title":"Endosomal Escape and Delivery of CRISPR\/Cas9 Genome Editing Machinery Enabled by Nanoscale Zeolitic Imidazolate Framework","volume":"140","author":"Alsaiari","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2022.114616_b0610","doi-asserted-by":"crossref","unstructured":"M. Qiu, Z. Glass, J. Chen, M. Haas, X. Jin, X. Zhao, X. Rui, Z. Ye, Y. Li, F. Zhang, Q. Xu, Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3, Proc. Natl. Acad. Sci. 118 (2021) e2020401118. 10.1073\/pnas.2020401118.","DOI":"10.1073\/pnas.2020401118"},{"key":"10.1016\/j.addr.2022.114616_b0615","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41565-019-0539-2","article-title":"A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing","volume":"14","author":"Chen","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2022.114616_b0620","doi-asserted-by":"crossref","first-page":"e1609","DOI":"10.1002\/wnan.1609","article-title":"Strategies for nonviral nanoparticle-based delivery of CRISPR\/Cas9 therapeutics., Wiley Interdiscip","volume":"12","author":"Chen","year":"2020","journal-title":"Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.addr.2022.114616_b0625","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/s41551-017-0137-2","article-title":"Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair","volume":"1","author":"Lee","year":"2017","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.addr.2022.114616_b0630","doi-asserted-by":"crossref","first-page":"4903","DOI":"10.1073\/pnas.1712963115","article-title":"Nonviral gene editing via CRISPR\/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide","volume":"115","author":"Wang","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2022.114616_b0635","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1021\/acs.accounts.1c00500","article-title":"Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing","volume":"54","author":"Qiu","year":"2021","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.addr.2022.114616_b0640","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2022.114616_b0645","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.actbio.2015.12.036","article-title":"High content analysis platform for optimization of lipid mediated CRISPR-Cas9 delivery strategies in human cells","volume":"34","author":"Steyer","year":"2016","journal-title":"Acta Biomater."},{"key":"10.1016\/j.addr.2022.114616_b0650","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.actbio.2019.04.020","article-title":"Scaffold-mediated non-viral delivery platform for CRISPR\/Cas9-based genome editing","volume":"90","author":"Chin","year":"2019","journal-title":"Acta Biomater."},{"key":"10.1016\/j.addr.2022.114616_b0655","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2019.11.005","article-title":"Rational designs of in vivo CRISPR-Cas delivery systems","volume":"168","author":"Xu","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114616_b0660","unstructured":"J. Neufeld, E. Muenzer, The Mucopolysaccharidosis., in: V. CR, Scriver AL, Beaudet WS, Sly D, Valle B, Childs KW, Kinzler B (Ed.), Metab. Mol. Basis Inherit. Dis., 8 ed., New York, 2001: pp. 3421\u201352."},{"key":"10.1016\/j.addr.2022.114616_b0665","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10545-017-0052-4","article-title":"Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I","volume":"40","author":"Penati","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.addr.2022.114616_b0670","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/jimd.12414","article-title":"Mucopolysaccharidoses type I gene therapy","author":"Hurt","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.addr.2022.114616_b0675","first-page":"6978303","article-title":"Induced Pluripotent Stem Cell Derivation and Ex Vivo Gene Correction Using a Mucopolysaccharidosis Type 1 Disease Mouse Model","author":"Miki","year":"2019","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.addr.2022.114616_b0680","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1182\/blood-2014-12-615492","article-title":"In vivo genome editing of the albumin locus as a platform for protein replacement therapy","volume":"126","author":"Sharma","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.addr.2022.114616_b0685","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.ymgme.2014.12.065","article-title":"ZFN-mediated genome editing of albumin safe harbor in vivo results in supraphysiological levels of human IDS, IDUA and GBA in mice","volume":"114","author":"DeKelver","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2022.114616_b0690","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.omtm.2020.06.022","article-title":"Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease","volume":"18","author":"Ernst","year":"2020","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"10.1016\/j.addr.2022.114616_b0695","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.ymthe.2020.03.018","article-title":"A Highly Efficacious PS Gene Editing System Corrects Metabolic and Neurological Complications of Mucopolysaccharidosis Type I","volume":"28","author":"Ou","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2022.114616_b0700","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nbt.4219","article-title":"Cas9-mediated allelic exchange repairs compound heterozygous recessive mutations in mice","volume":"36","author":"Wang","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2022.114616_b0705","doi-asserted-by":"crossref","unstructured":"R.S. Schuh, E.A. Gonzalez, A.M.V. Tavares, B.G. Seolin, L. de S. Elias, L.N.P. Vera, F. Kubaski, E. Poletto, R. Giugliani, H.F. Teixeira, U. Matte, G. Baldo, Neonatal nonviral gene editing with the CRISPR\/Cas9 system improves some cardiovascular, respiratory, and bone disease features of the mucopolysaccharidosis I phenotype in mice, Gene Ther. 27 (2020) 74\u201384. 10.1038\/s41434-019-0113-4.","DOI":"10.1038\/s41434-019-0113-4"},{"key":"10.1016\/j.addr.2022.114616_b0710","doi-asserted-by":"crossref","first-page":"e3410","DOI":"10.1002\/jgm.3410","article-title":"Brain and visceral gene editing of mucopolysaccharidosis I mice by nasal delivery of the CRISPR\/Cas9 system","volume":"24","author":"Vera","year":"2022","journal-title":"J. Gene Med."},{"key":"10.1016\/j.addr.2022.114616_b0715","doi-asserted-by":"crossref","unstructured":"J. Muenzer, Overview of the mucopolysaccharidoses., Rheumatology (Oxford). 50 Suppl 5 (2011) v4-12. 10.1093\/rheumatology\/ker394.","DOI":"10.1093\/rheumatology\/ker394"},{"key":"10.1016\/j.addr.2022.114616_b0720","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21186812","article-title":"Mucolipidoses Overview: Past, Present, and Future","volume":"21","author":"Khan","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2022.114616_b0725","author":"Santos","year":"2021","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.addr.2022.114616_b0730","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s11095-018-2503-5","article-title":"Nasal Administration of Cationic Nanoemulsions as Nucleic Acids Delivery Systems Aiming at Mucopolysaccharidosis Type I Gene Therapy","volume":"35","author":"Schuh","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2022.114616_b0735","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.119.258152","article-title":"Nose-to-brain delivery","author":"Wang","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.addr.2022.114616_b0740","doi-asserted-by":"crossref","DOI":"10.1080\/21678707.2020.1715208","article-title":"The potential of gene therapy for mucopolysaccharidosis type I","author":"Vera","year":"2020","journal-title":"Expert Opin. Orphan Drugs."},{"key":"10.1016\/j.addr.2022.114616_b0745","doi-asserted-by":"crossref","unstructured":"C.L. Christensen, R.E. Ashmead, F.Y.M. Choy, Cell and Gene Therapies for Mucopolysaccharidoses: Base Editing and Therapeutic Delivery to the CNS., Dis. (Basel, Switzerland). 7 (2019). 10.3390\/diseases7030047.","DOI":"10.3390\/diseases7030047"},{"key":"10.1016\/j.addr.2022.114616_b0750","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ymgme.2014.12.001","article-title":"Therapies for the bone in mucopolysaccharidoses","volume":"114","author":"Tomatsu","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2022.114616_b0755","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ymgme.2016.09.003","article-title":"Reversal of established bone pathology in MPS VII mice following lentiviral-mediated gene therapy","volume":"119","author":"Derrick-Roberts","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2022.114616_b0760","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.omtm.2020.05.015","article-title":"Liver-Targeted AAV8 Gene Therapy Ameliorates Skeletal and Cardiovascular Pathology in a Mucopolysaccharidosis IVA Murine Model","volume":"18","author":"Sawamoto","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.addr.2022.114616_b0765","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.omtm.2020.09.012","article-title":"Ex Vivo Gene Therapy Treats Bone Complications of Mucopolysaccharidosis Type II Mouse Models through Bone Remodeling Reactivation","volume":"19","author":"Wada","year":"2020","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"10.1016\/j.addr.2022.114616_b0770","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1080\/17425247.2016.1202235","article-title":"Nanotechnology applied to treatment of mucopolysaccharidoses","volume":"13","author":"Schuh","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2022.114616_b0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2018.06.049","article-title":"Intra-articular nonviral gene therapy in mucopolysaccharidosis I mice","author":"Bidone","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2022.114616_b0780","doi-asserted-by":"crossref","first-page":"22131","DOI":"10.1038\/srep22131","article-title":"AAV Gene Therapy for MPS1-associated Corneal Blindness","volume":"6","author":"Vance","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2022.114616_b0785","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.omtm.2020.05.014","article-title":"Ocular Tolerability and Immune Response to Corneal Intrastromal AAV-IDUA Gene Therapy in New Zealand White Rabbits","volume":"18","author":"Song","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.addr.2022.114616_b0790","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.ymthe.2020.04.004","article-title":"Intrastromal Gene Therapy Prevents and Reverses Advanced Corneal Clouding in a Canine Model of Mucopolysaccharidosis I","volume":"28","author":"Miyadera","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2022.114616_b0795","first-page":"S104","article-title":"CHAMPIONS: A phase 1\/2 clinical trial with dose escalation of SB-913 ZFN-mediated in vivo human genome editing for treatment of MPS II (Hunter syndrome)","volume":"126","author":"Muenzer","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2022.114616_b0800","first-page":"S68","article-title":"EMPOWERS: A phase 1\/2 clinical trial of SB-318 ZFN-mediated in vivo human genome editing for treatment of MPS I (Hurler syndrome) Paul","volume":"126","author":"Harmatz","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2022.114616_b0805","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nbt1018-907","article-title":"Sangamo\u2019s landmark genome editing trial gets mixed reception","volume":"36","author":"Sheridan","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2022.114616_b0810","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2022.114616_b0815","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2017.00182","article-title":"Regulatory and scientific advancements in gene therapy: State-of-the-art of clinical applications and of the supporting european regulatory framework","volume":"4","author":"Carvalho","year":"2017","journal-title":"Front. Med."},{"key":"10.1016\/j.addr.2022.114616_b0820","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current Clinical Applications of In Vivo Gene Therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2022.114616_b0825","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.2217\/rme-2017-0095","article-title":"Ex vivo and in vivo genome editing: A regulatory scientific framework from early development to clinical implementation","volume":"12","author":"Bachtarzi","year":"2017","journal-title":"Regen. Med."},{"key":"10.1016\/j.addr.2022.114616_b0830","doi-asserted-by":"crossref","DOI":"10.1186\/s40169-019-0244-7","article-title":"From fiction to science: clinical potentials and regulatory considerations of gene editing","volume":"8","author":"Schacker","year":"2019","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.addr.2022.114616_b0835","unstructured":"European Parliament, Regulation (EC) No. 1394\/2007 of the European Parliament and of the Council of 13 November 2007 on Advanced Therapy Medicinal Products and Amending Directive 2001\/83\/EC and Regulation \/EC) No 726\/2004., (2007). https:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=OJ:L:2007:324:0121:0137:en:PDF (accessed August 31, 2021)."},{"key":"10.1016\/j.addr.2022.114616_b0840","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2019.00921","article-title":"Regulatory framework for advanced therapy medicinal products in Europe and United States","volume":"10","author":"Iglesias-L\u00f3pez","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.addr.2022.114616_b0845","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115490","article-title":"Gene therapy for mucopolysaccharidosis type ii\u2014a review of the current possibilities","volume":"22","author":"Zapolnik","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2022.114616_b0850","first-page":"1","article-title":"Therapeutic genome editing: regulatory horizons","author":"Hines","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2022.114616_b0855","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jcyt.2020.11.008","article-title":"Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States","volume":"23","author":"Iglesias-Lopez","year":"2021","journal-title":"Cytotherapy."},{"key":"10.1016\/j.addr.2022.114616_b0860","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics13030347","article-title":"Advanced therapy medicinal products for the eye: Definitions and regulatory framework","volume":"13","author":"L\u00f3pez-Paniagua","year":"2021","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.addr.2022.114616_b0865","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1016\/j.clinthera.2021.02.006","article-title":"Advanced Therapies and Regulatory Framework in Different Areas of the Globe: Past, Present, and Future","volume":"43","author":"Pimenta","year":"2021","journal-title":"Clin. Ther."},{"key":"10.1016\/j.addr.2022.114616_b0870","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/aps.2017.2","article-title":"Therapeutic gene editing: Delivery and regulatory perspectives","volume":"38","author":"Shim","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.addr.2022.114616_b0875","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.tibtech.2018.06.005","article-title":"The Human Genome Editing Race: Loosening Regulatory Standards for Commercial Advantage?","volume":"37","author":"Cathomen","year":"2019","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.addr.2022.114616_b0880","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.tibtech.2014.12.001","article-title":"Quantifying on- and off-target genome editing","volume":"33","author":"Hendel","year":"2015","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.addr.2022.114616_b0885","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1182\/blood-2016-01-678136","article-title":"Ethical and regulatory aspects of genome editing","volume":"127","author":"Kohn","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.addr.2022.114616_b0890","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","article-title":"The promise and challenge of therapeutic genome editing","volume":"578","author":"Doudna","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.addr.2022.114616_b0895","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/nrd.2018.200","article-title":"European regulatory experience with advanced therapy medicinal products","volume":"18","author":"Barkholt","year":"2018","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X22005063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X22005063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:36:42Z","timestamp":1759210602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X22005063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":179,"alternative-id":["S0169409X22005063"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2022.114616","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene editing strategies to treat lysosomal disorders: The example of mucopolysaccharidoses","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2022.114616","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114616"}}